INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE;UNIVERSITÉ DE LILLE
发明人:
GIACOBINI, Paolo,PREVOT, Vincent
申请号：
EPEP2018/056330
公开号：
WO2018/177746A1
申请日:
2018.03.14
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use to rescue ovulation and fertility in postpuberal PCOS affected individuals.La présente invention concerne le domaine du traitement thérapeutique du syndrome des ovaires polykystiques (SOPK). Le syndrome des ovaires polykystiques, SOPK, est le trouble reproducteur féminin le plus commun contre lequel aucune solution thérapeutique n'est disponible, au-delà des changements du mode de vie. Les inventeurs ont maintenant démontré en utilisant des modèles précliniques in vivo, que les individus affectés par le SOPK ont une production élevée anormale de l'hormone libérant de la gonadotrophine (GnRH) et que cette production élevée de GnRH a été transmise à leur progéniture qui développent également le SOPK. En outre, en examinan
